Evidence map›Paper›PMID 32314298›Full record

ArticleClinical drug investigation2020

Comparative Study of Traditional Ablative CO

Bhavana Rajbanshi, Liangliang Shen, Miao Jiang, Qingyu Gao, Xin Huang, Jiaoyang Ma, Jihong Wang, Yang Hu, Hongli Lv, Xiao Wu and 1 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical drug investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. COLasers in medical science · 2025
    Article
  3. Efficacy of Fractional Versus Fully Ablative CODermatology practical & conceptual · 2024
    Article
  4. COSkin appendage disorders · 2024
    Article
  5. Review
  6. Review
  7. Review
  8. Fractional COLasers in surgery and medicine · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Bhavana RajbanshiDepartment of Dermatology and Venereology, Shanghai Tongji Hospital, Tongji University School of Medicine, 398 Xincun road, Putou District, Shanghai, China.
Liangliang ShenDepartment of Dermatology and Venereology, Shanghai Tongji Hospital, Tongji University School of Medicine, 398 Xincun road, Putou District, Shanghai, China.
Miao JiangDepartment of Dermatology and Venereology, Shanghai Tongji Hospital, Tongji University School of Medicine, 398 Xincun road, Putou District, Shanghai, China.
Qingyu GaoDepartment of Dermatology and Venereology, Shanghai Tongji Hospital, Tongji University School of Medicine, 398 Xincun road, Putou District, Shanghai, China.
Xin HuangDepartment of Dermatology and Venereology, Shanghai Tongji Hospital, Tongji University School of Medicine, 398 Xincun road, Putou District, Shanghai, China.
Jiaoyang MaDepartment of Dermatology and Venereology, Putuo District Central Hospital, Shanghai, China.
Jihong WangDepartment of Dermatology and Venereology, Jiading District Anting Hospital, Shanghai, China.
Yang HuDepartment of Dermatology and Venereology, Jiading District Nanxiang Hospital, Shanghai, China.
Hongli LvDepartment of Dermatology and Venereology, Jiading District Central Hospital, Shanghai, China.
Xiao WuDepartment of Dermatology and Venereology, Shanghai Tongji Hospital, Tongji University School of Medicine, 398 Xincun road, Putou District, Shanghai, China.
Jingjun ZhaoDepartment of Dermatology and Venereology, Shanghai Tongji Hospital, Tongji University School of Medicine, 398 Xincun road, Putou District, Shanghai, China. zhaojingjun2015@aliyun.com.
Tongji University · CNJiading District Central Hospital · CNTongji Hospital · CNCentral Hospital of Putuo District · CN

Funding

Shanghai Shen Kang Hospital Development Center 16CR4034A
6 · The paper itself

Abstract

backgroundThe predominance of onychomycosis has been increasing recently. New medications and treatment modalities are being researched for better saturation of the antifungal agents through the nail plate topically because of the low resilience of some patients for the oral antifungal agents. Treatment of onychomycosis, mainly moderate to severe, can be very challenging, expensive, and time consuming.

objectiveThe objective of this clinical trial is to compare the efficacy and safety of a manually operated ablative CO STUDY

designWe conducted an open-label controlled prospective study of 160 eligible patients randomized into control and treatment groups with a 1:1 allocation in the department of dermatology in five different hospitals in Shanghai. It was a 6-month study where both groups were treated with a topical antifungal agent, with the treatment group also receiving ablation by the traditional CO

resultsThe clinical efficacy and mycological cure rate were significantly higher (p < 0.001) for the treatment group. Three (3.75%) patients from the control group and 18 (25%) patients from the treatment group achieved complete nail clearance along with negative potassium hydroxide and negative culture (primary endpoint) results at 24 weeks. Mycological clearance with at least moderate nail clearance (secondary endpoint) for the treatment group was also significantly higher (p < 0.001) for the laser treatment group. The laser treatment was mildly painful but tolerable by the patients. No drug interactions for both groups were encountered.

conclusionsThe ablative CO

Indexed as

Laser TherapyAdministration, TopicalAdultAntifungal AgentsCarbon DioxideChinaCombined Modality TherapyFemaleHumansMaleMiddle AgedOnychomycosisProspective StudiesYoung AdultAntifungal AgentsCarbon Dioxide

Identifiers

PMID32314298
OpenAlexW3017181711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.